The main objectives of the laboratory are to understand the cellular and molecular mechanisms regulating pulmonary inflammation and its resolution, with the goal of developing anti-inflammatory or dual anti-microbial and anti-inflammatory therapeutics. We currently focus on two primary lung diseases: 1) Cystic Fibrosis (CF) and, 2) Acute Respiratory Distress Syndrome (ARDS), and are specifically interested in understanding how MAPK signaling pathways regulate leukocyte responses to inflammation and infection. Our laboratory utilizes both in vitro and in vivo models in our experimental design to investigate the regulators of inflammation.